There were no significant differences between the tamoxifen sensitive and the de novo tamoxifen resistant breast cancers in the relative expression of any of the coactivators to corepressor RNA, or in the relative expression of SRA/AIB1 RNA, or in expression of any of these coregulator RNAs relative to ORα or total ORβ RNA expression. The gene discussed is NCOA3; the disease is breast carcinoma.